Android Apple

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

By CNBC   |   3 weeks ago
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

Amgen's weight loss injection, MariTide, showed promising results in a mid-stage trial, with patients losing up to 20% of weight on average. Despite a slight share drop, Amgen aims to compete in the growing obesity drug market, offering a new approach to weight loss.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.